BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
BeiGene a global biotechnology company, that the U.S. Food and Drug Administration (FDA) has approved its Bruton’s tyrosine kinase inhibitor (BTKi).
Latest Press Releases
The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.
— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
Sai Life Sciences opens new High-Potency API Manufacturing facility at its Bidar Campus
Sai Life Sciences, one of India's fastest growing Contract Research, Development & Manufacturing Organizations (CRO-CDMO), the opening of a new High-Potency API (HPAPI) manufacturing facility at its cGMP API Manufacturing campus in Bidar, India.
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®)
Servier and Taiho Oncology, Inc., the release of data from SUNLIGHT, a pivotal Phase 3 global trial evaluating the combination of trifluridine/tipiracil (LONSURF®).
Canada Royal Enoch Phytomedicine Launches Clinical Trial
Canada Royal Enoch Phytomedicine Ltd., an innovative leader in ginseng and ginsenosides research and application, has the launch of a new clinical trial.
Harrow Announces Availability of Fortisite™ Formulations for In-Office Use
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, the availability, for in-office use, of Fortisite™ (compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx® 503B outsourcing facility.
CollPlant Enriches Portfolio of rhCollagen
CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing.